TSL (Tissue Science Laboratories) set to strengthen Euro side with new agreements
This article was originally published in Clinica
AIM-quoted UK company Tissue Science Laboratories will build up its European activities with new distribution agreements in key potential markets in the coming months. The company, which specialises in porcine dermis products for the replacement and repair of human tissue, saw its European sales (including UK) more than double to around £1bn ($1.56bn) in 2002, in a year described by CEO Martin Hunt as one of "good progress".
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.